Glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®, Zepbound™), among others, are an exciting advance in the treatment of obesity/overweight and diabetes mellitus. But are GLP-1 receptor agonists associated with an increased risk of suicidal ideation or behavior? Why are we discussing this? The United States Food and Drug Administration (FDA),…